Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aytu BioPharmaAYTU -0.46%40 Receivables Turnover is 0.45 as of Mar. 2026. GuruFocus rates AYTU with a GF Score™ of 40/100 and a GF Value™ of $0.85 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 948 Drug Manufacturers companies, Aytu BioPharma ranks worse than 93.67% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Aytu BioPharma's Revenue for the
three
months ended in Mar. 2026 was $12.41 Mil. Aytu BioPharma's average Accounts Receivable for the
three
months ended in Mar. 2026 was $27.71 Mil.
Hence, Aytu BioPharma's Receivables Turnover for the
three
months ended in Mar. 2026 was 0.45.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Aytu BioPharma Receivables Turnover Related Terms
Aytu BioPharma Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Aytu BioPharma's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AYTU vs TXMD, CPHI, RMTI: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Aytu BioPharma's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aytu BioPharma Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aytu BioPharma's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Aytu BioPharma's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aytu BioPharma (AYTU) has a Receivables Turnover of 0.45 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Aytu BioPharma and its competitors. According to the industry distribution chart, Aytu BioPharma ranks #888 out of 948 companies in the Drug Manufacturers industry, placing it in the top 93.7%.
Is Aytu BioPharma's Receivables Turnover too high?
Aytu BioPharma's current Receivables Turnover is 0.45. The Drug Manufacturers industry median Receivables Turnover is 5.07. Aytu BioPharma's value of 0.45 is 91.1% below this industry median. Based on the distribution chart, Aytu BioPharma ranks #888 out of 948 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Aytu BioPharma has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aytu BioPharma's Receivables Turnover compare to TXMD and CPHI?
According to the Drug Manufacturers industry distribution chart, Aytu BioPharma ranks #888 out of 948 companies for Receivables Turnover. This places Aytu BioPharma in the lower half of its industry. The industry median Receivables Turnover is 5.07. Aytu BioPharma's value of 0.45 is 91.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 948 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aytu BioPharma's current Receivables Turnover of 0.45 is 91.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Aytu BioPharma and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aytu BioPharma's current Receivables Turnover is 0.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aytu BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Aytu BioPharma (AYTU) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.85, compared to a current price of $2.15 — trading 152.9% above its estimated fair value. The current Receivables Turnover is 0.45 and 91.1% below the Drug Manufacturers industry median of 5.07. Aytu BioPharma's overall GF Score™ is 40/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Aytu BioPharma (AYTU), the current Receivables Turnover is 0.45 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aytu BioPharma (AYTU) Overvalued in 2026?
Based on GuruFocus' analysis, Aytu BioPharma stock appears to be overvalued.
The current stock price of $2.15 is trading 152.9% above its estimated GF Value™ of $0.85.
GuruFocus considers Aytu BioPharma to be Significantly Overvalued.
Key valuation signals for AYTU:
Receivables Turnover: 0.45
GF Value™: $0.85 vs. price of $2.15 (152.9% above fair value)
Industry Position: 91.1% below the Drug Manufacturers median (#888 of 948)
No single metric tells the full story. See the AYTU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
40GF Score
Get the complete analysis for AYTU
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AYTU has been successfully added to your 
